[go: up one dir, main page]

ATE433996T1 - Humane dr4-antikörper und deren anwendungen - Google Patents

Humane dr4-antikörper und deren anwendungen

Info

Publication number
ATE433996T1
ATE433996T1 AT02805988T AT02805988T ATE433996T1 AT E433996 T1 ATE433996 T1 AT E433996T1 AT 02805988 T AT02805988 T AT 02805988T AT 02805988 T AT02805988 T AT 02805988T AT E433996 T1 ATE433996 T1 AT E433996T1
Authority
AT
Austria
Prior art keywords
antibodies
human
applications
kits
diagnosis
Prior art date
Application number
AT02805988T
Other languages
English (en)
Inventor
Anan Chuntharapai
Kyung Kim
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Application granted granted Critical
Publication of ATE433996T1 publication Critical patent/ATE433996T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2510/00—Detection of programmed cell death, i.e. apoptosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT02805988T 2001-07-03 2002-06-29 Humane dr4-antikörper und deren anwendungen ATE433996T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US30322001P 2001-07-03 2001-07-03
PCT/US2002/020712 WO2003066661A2 (en) 2001-07-03 2002-06-29 Human dr4 antibodies and uses thereof

Publications (1)

Publication Number Publication Date
ATE433996T1 true ATE433996T1 (de) 2009-07-15

Family

ID=27734188

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02805988T ATE433996T1 (de) 2001-07-03 2002-06-29 Humane dr4-antikörper und deren anwendungen

Country Status (13)

Country Link
US (2) US7252994B2 (de)
EP (2) EP1409544B1 (de)
JP (1) JP4509570B2 (de)
AT (1) ATE433996T1 (de)
AU (2) AU2002366430B2 (de)
CA (1) CA2451680C (de)
CY (1) CY1110505T1 (de)
DE (1) DE60232660D1 (de)
DK (1) DK1409544T3 (de)
ES (1) ES2328234T3 (de)
IL (1) IL159527A0 (de)
PT (1) PT1409544E (de)
WO (1) WO2003066661A2 (de)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI318983B (en) 2000-05-02 2010-01-01 Uab Research Foundation An antibody selective for a tumor necrosis factor-related apoptosis-inducing ligand receptor and uses thereof
US7476383B2 (en) * 2000-05-02 2009-01-13 The Uab Research Foundation Antibody selective for DR4 and uses thereof
US20060062786A1 (en) * 2000-11-08 2006-03-23 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to TRAIL receptors
US20030228309A1 (en) * 2000-11-08 2003-12-11 Theodora Salcedo Antibodies that immunospecifically bind to TRAIL receptors
US20050129616A1 (en) * 2001-05-25 2005-06-16 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to TRAIL receptors
US20050214209A1 (en) * 2001-05-25 2005-09-29 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to TRAIL receptors
US7361341B2 (en) 2001-05-25 2008-04-22 Human Genome Sciences, Inc. Methods of treating cancer using antibodies that immunospecifically bind to trail receptors
US7348003B2 (en) 2001-05-25 2008-03-25 Human Genome Sciences, Inc. Methods of treating cancer using antibodies that immunospecifically bind to TRAIL receptors
US20090226429A1 (en) * 2001-05-25 2009-09-10 Human Genome Sciences, Inc. Antibodies That Immunospecifically Bind to TRAIL Receptors
US20030180296A1 (en) * 2001-12-20 2003-09-25 Theodora Salcedo Antibodies that immunospecifically bind to trail receptors
ES2239886B1 (es) * 2003-11-05 2006-12-16 Universidad De Barcelona Metodo y aparato para la determinacion de la viabilidad celular.
AU2012200602B2 (en) * 2004-08-06 2012-11-08 Genentech, Inc. Assays and methods using biomarkers
EP1778871B1 (de) 2004-08-06 2011-05-04 Genentech, Inc. Tests und verfahren unter verwendung von biomarkern
DK1774037T3 (da) * 2004-08-06 2011-08-15 Genentech Inc Analyser og fremgangsmåder, der anvender biomarkører
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
US8029783B2 (en) 2005-02-02 2011-10-04 Genentech, Inc. DR5 antibodies and articles of manufacture containing same
EP2287615A1 (de) * 2005-08-16 2011-02-23 Genentech, Inc. APO2L/TRAIL Apoptose Resistenz Prüfung mittels GALNAC-T14 Gewebeexpression
JP2007063225A (ja) * 2005-09-01 2007-03-15 Takeda Chem Ind Ltd イミダゾピリジン化合物
CA2626361C (en) * 2005-10-16 2016-08-16 David Wallach Pharmaceutical compositions and diagnostic methods for inflammatory skin diseases, disorders or conditions
US20070197532A1 (en) * 2005-11-18 2007-08-23 Cao Sheldon X Glucokinase activators
US8034822B2 (en) 2006-03-08 2011-10-11 Takeda San Diego, Inc. Glucokinase activators
US8008332B2 (en) * 2006-05-31 2011-08-30 Takeda San Diego, Inc. Substituted indazoles as glucokinase activators
EP2091947A2 (de) 2006-12-20 2009-08-26 Takeda San Diego, Inc. Glucokinaseaktivatoren
US8173645B2 (en) * 2007-03-21 2012-05-08 Takeda San Diego, Inc. Glucokinase activators
WO2011159928A2 (en) * 2010-06-16 2011-12-22 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Anti-dr4 agonist antibodies
CN109022465B (zh) 2011-10-28 2022-04-29 特瓦制药澳大利亚私人有限公司 多肽构建体及其用途
EP2684896A1 (de) 2012-07-09 2014-01-15 International-Drug-Development-Biotech Antikörper gegen die DR5-Familie, bispezifische oder multivalente Antikörper gegen die DR5-Familie und Verfahren zu deren Verwendung
US11117975B2 (en) 2013-04-29 2021-09-14 Teva Pharmaceuticals Australia Pty Ltd Anti-CD38 antibodies and fusions to attenuated interferon alpha-2B
EP2992013B1 (de) 2013-04-29 2019-12-04 Teva Pharmaceuticals Australia Pty Ltd Anti-cd38-antikörper und fusionen davon mit abgeschwächtem interferon-alpha-2b
UA119352C2 (uk) 2014-05-01 2019-06-10 Тева Фармасьютикалз Острейліа Пті Лтд Комбінація леналідоміду або помалідоміду і конструкції анти-cd38 антитіло-атенуйований інтерферон альфа-2b та спосіб лікування суб'єкта, який має cd38-експресуючу пухлину
EP3212216A4 (de) 2014-10-29 2018-04-18 Teva Pharmaceuticals Australia Pty Ltd Varianten von interferon alpha2b
CN116333125A (zh) * 2015-10-30 2023-06-27 银河生物技术有限责任公司 结合死亡受体4和死亡受体5的抗体
KR20180098567A (ko) 2015-12-01 2018-09-04 젠맵 비. 브이 항-dr5 항체 및 그의 사용 방법

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8905669D0 (en) * 1989-03-13 1989-04-26 Celltech Ltd Modified antibodies
DE59010908D1 (de) 1989-09-12 2000-08-10 Hoffmann La Roche TNF-bindende Proteine
AU1368292A (en) 1991-03-11 1992-10-06 Sheila Drover Murine monoclonal antibodies recognizing polymorphic determinants of hla
US5397703A (en) 1992-07-09 1995-03-14 Cetus Oncology Corporation Method for generation of antibodies to cell surface molecules
WO1995021256A1 (fr) 1994-02-04 1995-08-10 Bio Merieux Virus msrv1 et agent pathogene et/ou infectant msrv2 associes a la sclerose en plaques, leurs constituants nucleiques et leurs applications
DE69638346D1 (de) 1995-06-29 2011-05-05 Immunex Corp Cytokin welches Apoptose induziert
US6030945A (en) 1996-01-09 2000-02-29 Genentech, Inc. Apo-2 ligand
NZ334309A (en) 1996-10-25 2000-08-25 Human Genome Sciences Inc Neutrokine alpha protein, a member of the TNF family, and its use in treating and/or detecting immune disorders
US6017729A (en) 1996-12-23 2000-01-25 Immunex Corporation Receptor activator of NF-κB
JP4450870B2 (ja) 1997-01-28 2010-04-14 ヒューマン ジノーム サイエンシーズ， インコーポレイテッド 死ドメイン含有レセプター４（ｄｒ４：死レセプター４）、ｔｎｆ−レセプタースーパーファミリーのメンバーおよびｔｒａｉｌへの結合
US6433147B1 (en) 1997-01-28 2002-08-13 Human Genome Sciences, Inc. Death domain containing receptor-4
US6072047A (en) 1997-02-13 2000-06-06 Immunex Corporation Receptor that binds trail
US5969102A (en) 1997-03-03 1999-10-19 St. Jude Children's Research Hospital Lymphocyte surface receptor that binds CAML, nucleic acids encoding the same and methods of use thereof
US20010010924A1 (en) 1997-03-14 2001-08-02 Keith Charles Deen Tumor necrosis factor related receptor, tr6 polynecleotides
DE69836956T2 (de) 1997-03-17 2007-10-31 Human Genome Sciences, Inc. Rezeptor 5, der eine für den zelltod verantwortliche domäne enthält
EP1007562A4 (de) 1997-04-16 2000-09-27 Millennium Pharm Inc Tomornekrosefaktorrezeptor verwandte proteine tango-63d und tango-63e
JP2001526532A (ja) 1997-04-16 2001-12-18 アムジエン・インコーポレーテツド オステオプロテゲリン結合性蛋白および受容体
IL132067A0 (en) 1997-05-15 2001-03-19 Genentech Inc Apo-2 receptor
WO1999002653A1 (en) 1997-07-11 1999-01-21 Trustees Of The University Of Pennsylvania Nucleic acid encoding a novel chemotherapy-induced protein, and methods of use
AU9013998A (en) 1997-07-21 1999-02-10 Zymogenetics Inc. Tumor necrosis factor receptor ztnfr-5
EP1019502A2 (de) 1997-08-06 2000-07-19 Regeneron Pharmaceuticals, Inc. Humane waisenrezeptor ntr-1
US6417328B2 (en) 1997-08-15 2002-07-09 Thomas Jefferson Univeristy Trail receptors, nucleic acids encoding the same, and methods of use thereof
AU9376498A (en) 1997-09-05 1999-03-22 University Of Washington Tumor necrosis factor family receptors and ligands, encoding nucleic acids and related binding agents
AU2093499A (en) 1997-12-30 1999-07-19 Chiron Corporation Members of tnf and tnfr families
EP1053256B9 (de) * 1998-01-26 2012-01-18 Genentech, Inc. Antikörper gegen "death receptor 4" (dr4) und deren verwendungen
US20040180049A1 (en) * 1998-01-26 2004-09-16 Genentech, Inc. DR4 antibodies and uses thereof
US20040120947A1 (en) * 1998-01-26 2004-06-24 Genentech, Inc. DR4 antibodies and uses thereof
PT1086138E (pt) 1998-06-12 2010-01-04 Genentech Inc Anticorpos monoclonais, anticorpos de reacção cruzada e método para produzir os mesmos
US6252050B1 (en) * 1998-06-12 2001-06-26 Genentech, Inc. Method for making monoclonal antibodies and cross-reactive antibodies obtainable by the method
DE60042066D1 (de) 1999-05-28 2009-06-04 Genentech Inc Chimärische dr4 antikörper und ihre verwendung
US7291714B1 (en) * 1999-06-30 2007-11-06 Millennium Pharmaceuticals, Inc. Glycoprotein VI and uses thereof
US7279160B2 (en) 2000-05-02 2007-10-09 The Uab Research Foundation Combinations of DR5 antibodies and other therapeutic agents
CA2447602C (en) * 2001-05-18 2011-11-01 Kirin Beer Kabushiki Kaisha Anti-trail-r antibodies
CN100594935C (zh) 2001-05-25 2010-03-24 人体基因组科学有限公司 免疫特异性结合trail受体的抗体
RU2313368C2 (ru) 2001-11-01 2007-12-27 Ю Эй Би Рисерч Фаундейшн Комбинации антител, обладающих селективностью по отношению к рецептору лиганда, индуцирующему апоптоз, ассоциированный с фактором некроза опухоли, и других терапевтических средств
ES2357225T3 (es) 2001-11-01 2011-04-20 Uab Research Foundation Combinaciones de anticuerpos anti-dr5 y anticuerpos anti-dr4 y otros agentes terapéuticos.
AU2002352676A1 (en) 2001-11-14 2003-05-26 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to trail receptors

Also Published As

Publication number Publication date
ES2328234T3 (es) 2009-11-11
CA2451680A1 (en) 2003-08-14
EP1409544A2 (de) 2004-04-21
WO2003066661A3 (en) 2003-11-27
US20040147725A1 (en) 2004-07-29
EP2192130A1 (de) 2010-06-02
PT1409544E (pt) 2009-09-16
DK1409544T3 (da) 2009-10-26
US7744881B2 (en) 2010-06-29
JP4509570B2 (ja) 2010-07-21
IL159527A0 (en) 2004-06-01
AU2008260311A1 (en) 2009-01-15
JP2005517021A (ja) 2005-06-09
CY1110505T1 (el) 2015-04-29
AU2002366430A1 (en) 2003-09-02
EP1409544B1 (de) 2009-06-17
CA2451680C (en) 2011-04-19
AU2002366430B2 (en) 2008-09-18
EP1409544A4 (de) 2005-11-09
HK1065323A1 (en) 2005-02-18
US20080233646A1 (en) 2008-09-25
DE60232660D1 (de) 2009-07-30
WO2003066661A2 (en) 2003-08-14
US7252994B2 (en) 2007-08-07

Similar Documents

Publication Publication Date Title
ATE433996T1 (de) Humane dr4-antikörper und deren anwendungen
CY1111863T1 (el) Αντισωματα εναντιον υποδοχεα θανατου 4 (dr4) και χρησεις αυτων
CY1109151T1 (el) Αντισωματα dr4 και χρησεις αυτων
CY2020003I2 (el) Anti-il-12 αντισωματα, συνθεσεις, μεθοδοι και χρησεις για την θεραπευτικη αγωγη της παθολογιας του crohn
DE122012000001I1 (de) Humane antikorper gegen CTLA-4 und deren verwendungen.
ATE465257T1 (de) Agonisten für den rezeptor des hepatozyten- wachstumsfaktors und deren anwendungen
WO2004011611A3 (en) Taci antibodies and uses thereof
DE60314500D1 (de) Diaminopyrimidine und deren verwendung als angiogenesehemmer
NO20061736L (no) Krystallform av epotilon B
BR0107691A (pt) Sapogeninas substituìdas e seu uso
ATE325789T1 (de) Aminocyclohexylether-verbindungen und deren verwendung
MXPA04005847A (es) Compuestos derivados de 4-sulfuro/sulfoxido/sulfonil-1h-pirazolilo, para uso en enfermedades asociadas con el receptor 5-ht2c.
DE60137337D1 (de) Vorbeugende und therapeutsche monoklonale antikörper gegen vacciniavirusantigene
DE60313004D1 (de) Alpha-7-nikotinsäure-rezeptoragonisten und statine in kombination
DE602004017326D1 (de) Tetrahydrocarbazolderivate und deren pharmazeutische verwendung
DE60335610D1 (de) Neoplasma-spezifische antikörper und deren verwendungen
ID25478A (id) Agonis 5-ht1f
DE69832722D1 (de) L-threonat-eisen, pharmazeutische zusammensetzung und verwendung zur verbesserung und behandlung von anämie bei menschen
EP1498145A4 (de) LOCKSTOFF ZUR BEHANDLUNG UND/ODER PRÄVENTION VON Th2 CYTOKIN-ASSOZIIERTEN ALLERGISCHEN ERKRANKUNGEN, GATA3 MUTANT-PROTEIN UND DIESES ENTHALTENDE MEDIZINISCHE ZUSAMMENSETZUNGEN
ES2176642T3 (es) Utilizacion de la sulbutiamina para la obtencion de composiciones farmaceuticas utiles en el tratamiento de ciertos t rastornos psicomotores y psicointelectuales.
DE60336504D1 (de) 4-hydroxypiperidin-derivate zur verwendung als antimycobakterielle mittel

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1409544

Country of ref document: EP